脑膜瘤分子整合分级模型的建立与验证
本研究基于527例脑膜瘤患者发现队列,利用染色体拷贝数数据构建了整合有丝分裂计数和1p、3p、4、6、10、14q、18、19号染色体或CDKN2A缺失的三级分级方案(Integrated Grades 1-3),并在2个独立队列(共172例)中验证。结果显示32%的脑膜瘤被重新分类为更低或更高风险等级,且整合分级在预测复发风险方面优于WHO分级(基于时间依赖AUC、平均精度和Brier评分)。
要点
- 整合分级纳入有丝分裂计数和特定染色体/CDKN2A缺失,形成三级方案。
- 32%的脑膜瘤被重新分类为不同风险等级。
- 整合分级在预测无进展生存方面优于WHO分级。
核心结论
- 提出的脑膜瘤分子整合分级方案在预测无进展生存方面显著优于现行WHO分级系统。
- 该框架利用广泛可用的基因组技术,临床医生可相对容易地采用。
研究设计与样本
- 研究在527例脑膜瘤患者发现队列中使用Cox比例风险模型、随机生存森林和梯度提升构建模型。
- 模型在2个独立队列(共172例脑膜瘤患者)中使用正交基因组平台进行验证。
主要发现
- 32%的脑膜瘤被重新分类为更低风险或更高风险的整合分级,相比其分配的WHO分级。
- 整合分级在预测复发风险方面比WHO分级更准确,依据时间依赖AUC、平均精度和Brier评分确定。
关键数值与推荐
- 整合分级方案(Integrated Grades 1-3)纳入有丝分裂计数和1p、3p、4、6、10、14q、18、19号染色体或CDKN2A的缺失。
临床怎么用
- 临床医生可使用广泛可用的基因组技术采用该分子整合分级框架,以优化脑膜瘤患者的复发风险预测和管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Meningiomas are the most common primary intracranial tumor in adults. Clinical care is currently guided by the World Health Organization (WHO) grade assigned to meningiomas, a 3-tiered grading system based on histopathology features, as well as extent of surgical resection. Clinical behavior, however, often fails to conform to the WHO grade. Additional prognostic information is needed to optimize patient management. METHODS: We evaluated whether chromosomal copy-number data improved prediction of time-to-recurrence for patients with meningioma who were treated with surgery, relative to the WHO schema. The models were developed using Cox proportional hazards, random survival forest, and gradient boosting in a discovery cohort of 527 meningioma patients and validated in 2 independent cohorts of 172 meningioma patients characterized by orthogonal genomic platforms. RESULTS: We developed a 3-tiered grading scheme (Integrated Grades 1-3), which incorporated mitotic count and loss of chromosome 1p, 3p, 4, 6, 10, 14q, 18, 19, or CDKN2A. 32% of meningiomas reclassified to either a lower-risk or higher-risk Integrated Grade compared to their assigned WHO grade. The Integrated Grade more accurately identified meningioma patients at risk for recurrence, relative to the WHO grade, as determined by time-dependent area under the curve, average precision, and the Brier score. CONCLUSION: We propose a molecularly integrated grading scheme for meningiomas that significantly improves upon the current WHO grading system in prediction of progression-free survival. This framework can be broadly adopted by clinicians with relative ease using widely available genomic technologies and presents an advance in the care of meningioma patients.
引用
- Driver J, Hoffman SE, Tavakol S, et al. A molecularly integrated grade for meningioma. Neuro Oncol. 2022. PMID: 34508644. doi:10.1093/neuonc/noab213
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。